Company profiles

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Teva is among the top 15 global pharmaceutical companies, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Diseases of the central nervous system represent a key therapeutic area for Teva, with the company producing a world leading multiple sclerosis (MS) therapy. In neurology, Teva is dedicated to providing treatments for migraine and headache, movement disorders, neurodegenerative conditions and pain, and has late-stage development programs in a number of these neurological conditions. In Europe, Teva operates a number of research & development facilities, production and distribution centres, with the company’s European headquarters based in Amsterdam, the Netherlands
At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area.

As an emerging leader in Parkinson’s, our goal is to support the Parkinson’s community through medical research, educational initiatives and programs that help people with Parkinson’s. Founded in 1995, Acorda is focused on developing therapies to restore neurological function. We also have a strong commitment to the communities we serve through our extensive outreach programs and advocacy support, providing information and resources to help people with neurological disorders.
Kyowa Hakko Kirin Co., Ltd. is a global research-based life sciences company specialized in biotechnologies with over 8,000 employees. The core therapeutic areas are oncology, neuroscience, nephrology, and immunology and allergy. The company leverages leading-edge technologies to improve the health and well-being of people worldwide.
Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, is tirelessly dedicated to restoring brain health, so every person can be their best. Lundbeck has a long heritage of innovation in neuroscience and is focused on delivering transformative treatments that address unmet needs in brain health.
At US WorldMeds our mission is to market meaningful products that improve lives and result in a thriving community of patients. We hold a fundamental belief that our science has the potential to improve the lives of Parkinson’s patients. US WorldMeds’ commitment to Parkinson’s patients is reflected in all that we do. Our pipeline of development projects, along with our two currently available PD treatments, reflects our resolve to bring innovative solutions to Parkinson’s patients.
Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company. We specialise in innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease
BIAL is an innovative international pharmaceutical company. Strongly committed to therapeutic innovation, investing 20% of its turnover in R&D, BIAL has established an ambitious R&D program centred on neurosciences and cardiovascular system.
BIAL expects to strengthen its international presence by continuing to deliver innovative medicines to healthcare professionals, patients and their families, always inspired by its strong motivation: “Keeping life in mind”.

Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as 'giving first thought to patients and their families and to increasing the benefits health care provides', which we call our human health care philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
GW Pharmaceuticals (GW) is a pioneering, global biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and medicines. GW’s mission is to transform the lives of patients with rare and severe illnesses through developing and delivering rigorously tested cannabinoid-based pharmaceutical medicines with well documented safety and efficacy profiles, manufactured to the highest pharmaceutical standards and approved by medicines regulators.
The Company’s extended pipeline covers a range of therapeutic areas including neurology, oncology and psychiatry. GW is listed on the NASDAQ Global Market (GWPH).

Forum 1, Novartis Campus CH-4056 Basel
Telephone: +41 61 324 1111
Fax: +41 61 324 8001
Our strategy: We believe Novartis is well prepared for a world with a growing, aging population and continuously evolving healthcare needs. We have a clear mission, focused strategy and strong culture, all of which we expect will support the creation of value over the long term for our company, our shareholders and society.
Our strategy is to use science-based innovation to deliver better patient outcomes in growing areas of healthcare.

Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Marlborough, Massachusetts, 01752
Telephone: +1800-394-7377
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
At Amneal, it’s our mission to make healthy possible for people affected by Parkinson’s disease. We believe in partnering with patients, care partners, healthcare providers, and advocacy organizations—because together, we can achieve so much more.

Grifols is a global healthcare company dedicated to improving the health and well-being of people around the world.
Established in Barcelona, Spain in 1940, we are an industry leader in plasma-derived medicines, and provide hospitals and healthcare professionals with the tools, information and services they need to deliver expert medical care.
With over 20,000 employees across 30 countries, our Bioscience, Diagnostic, Hospital and Bio Supplies divisions develop, manufacture and market innovative products and services available in more than 100 countries.

Intec Pharma is a biopharmaceutical company developing drugs based on its proprietary Accordion Pill platform technology. The Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, is in Phase 3 development for the treatment of Parkinson's disease symptoms, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for pain indications.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Sanofi Genzyme
500 Kendall Street,
Cambridge, MA 02142
VP Media Relations
Contact person: Erin Pascal
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Learn more at
A clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. We are defined by our core competencies including deep therapeutic knowledge and operational effectiveness.
Oryzon is a public clinical stage biopharmaceutical company, leader in the development of epigenetics-based therapies with three programs:
- Vafidemstat (ORY-2001), a dual LSD1-MAOB inhibitor, is currently in three Phase IIA trials: "ETHERAL": in mild to moderate AD, "REIMAGINE": aggression in ADHD, BPD, ASD, LBD and AD, and "SATEEN": in RRMS and SPMS.
- Iadademstat (ORY-1001) is a selective LSD1 inhibitor. It is currently in two Phase IIA trials: "ALICE": in AML and "CLEPSIDRA": in SCLC.
- ORY-3001, a third epigenetic compound, also against LSD1, currently in the final stage of preclinical development, for a yet undisclosed non-oncological indication.
UCB Inspired by Patients. Driven by Science UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With more than 7,500 people in approximately 40 countries, UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_Iberia
CeGaT GmbH
Paul-Ehrlich-Str. 23
72076 Tuebingen, Germany
CeGaT is a leading global provider of genetic diagnostics and mutation-related disease analyses. The company combines its next-generation sequencing (NGS) process and analysis pipelines with its medical expertise - dedicated to identifying the genetic cause of disease and supporting patient management. Genetic mutations can trigger a wide range of diseases, from epilepsy to Parkinson’s. Through the use of NGS, it is possible to analyze all genes associated with a disease phenotype simultaneously – both fast and effectively. An interdisciplinary team of scientists and human geneticists evaluates the data and summarizes the findings in a comprehensive medical report. All services are performed in-house. CeGaT, founded in 2009 and based in Tübingen, Germany, is accredited according to CAP, CLIA and DIN EN ISO 15189:2014. The company provides human genetics services worldwide.

Wisepress Medical Bookshop
25 High Path, Merton Abbey,
London, SW19 2JL UK
Telephone: +44 20 8715 1812
Fax: +44 20 8715 1722
Website:, Europe's leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.